Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
DSIP
Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
A naturally occurring nonapeptide first isolated from rabbit brain in 1977. Studied for its role in sleep regulation, stress response, and pain modulation. Popular in the biohacking community for sleep optimization.
A nonapeptide (9 amino acids) first isolated from rabbit cerebral venous blood in 1977. Originally studied for sleep-induction properties, it is now being investigated for opioid withdrawal and chronic insomnia.
Modulates sleep architecture by influencing GABA, serotonin, and glutamate signaling. Promotes slow-wave (delta) sleep without suppressing REM. Also appears to modulate cortisol and ACTH, potentially reducing stress-related sleep disruption.
Modulates the sleep-wake cycle through interactions with opioid, serotonin, and other neurotransmitter systems. Reduces the activity of stress-response systems. Mechanism is not fully characterized, but effects appear to be on circadian regulation and stress adaptation.
- Sleep quality improvement
- Stress reduction
- Pain modulation
- Recovery optimization
- Circadian rhythm regulation
- Sleep quality improvement
- Opioid withdrawal support
- Stress and cortisol reduction
- Chronic insomnia
- Narcolepsy (investigational)
- Limited human clinical data
- Short half-life (minutes) limits practical use
- Injection site reactions
- May cause morning grogginess at higher doses
- Long-term safety unknown
- Limited human clinical data
- Mechanism not fully understood
- Potential interactions with opioid medications
- Inconsistent results across studies
- Long-term effects unknown
No FDA regulatory category. Available only as a research chemical. Not approved for any clinical indication in the US.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026 for opioid withdrawal, chronic insomnia, and narcolepsy indications. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
- Delta sleep-inducing peptide (DSIP): a review
1984 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.